First-pass extracted concept

immune checkpoint inhibitors

Candidate: concept label4 source documents3 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

ICIs

Extracted Explainers

What the tool is doing

Immune checkpoint inhibitors are described as a way to reverse T-cell exhaustion in HIV-1 cure strategies.

Source 1DOI PubMed

Immune checkpoint inhibitors are discussed as cancer immunotherapy agents whose use can unleash paraneoplastic neurological syndromes. In this review they function as a trigger category rather than as a toolkit component.

Source 4DOI PubMed

What problem it solves

They address immune dysfunction associated with exhausted T cells.

Source 1DOI PubMed

The review uses ICIs to explain how altered cancer immunity may precipitate neurological autoimmunity.

Source 4DOI PubMed

What it does not solve

The abstract does not present ICIs as a method for diagnosing or engineering encephalitis-related systems.

Source 4DOI PubMed

Alternatives

The review contrasts checkpoint-inhibitor triggering with other trigger classes including tumor genetic features, preceding infections, and host HLA-related susceptibility.

Source 4DOI PubMed

Evidence Snippets

reversal of T-cell exhaustion using immune checkpoint inhibitors

Evidence 1Source 1DOI PubMedprovenance

immune checkpoint inhibitors (ICIs) such as atezolizumab and nivolumab, have shown promising outcomes

Evidence 2Source 2DOI PubMedprovenance

Recent advances in the clinical application of immune checkpoint inhibitors, combination therapy strategies, and mechanisms of resistance are discussed.

Evidence 3Source 3DOI PubMedprovenance

Despite their rarity, PNSs offer a unique perspective to understand the complex interplay between cancer immunity, effect of immune checkpoint inhibitors (ICIs)... In particular, it is reported that ICI treatment can unleash PNSs.

Evidence 4Source 4DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 0 linked claims

Source 2primary paper2025MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 3primary paper2025MEDDOI PubMed

1 evidence snippet 0 linked claims

Source 4review2020Therapeutic Advances in Neurological DisordersDOI PubMed

1 evidence snippet 2 linked claims Claim 1 Claim 2

Linked Claims

Claim 1combination therapy outcomesupports2025Source 2DOI PubMed

Immune checkpoint inhibitors such as atezolizumab and nivolumab show promising outcomes when combined with anti-VEGF treatments in hepatocellular carcinoma.

Claim 2biomarker relevancesupports2020Source 4DOI PubMed

Pathological substrates seen in PNS-related tumors have gained attention as potential biomarkers of immune checkpoint inhibitor sensitivity and oncological prognosis.

Quoted textsource-backed

similar pathological substrates have gained further attention as potential biomarkers of ICI-sensitivity and oncological prognosis

Claim 3triggering factorsupports2020Source 4DOI PubMed

Immune checkpoint inhibitor treatment can unleash paraneoplastic neurological syndromes.

Quoted textsource-backed

In particular, it is reported that ICI treatment can unleash PNSs